ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2067

Dermal Fibroblasts from Patients with Lupus Nephritis Express an Anti-Fibrotic Transcriptome

Robert M Clancy1, Evan Der2, Kemal Akat3, Anna R. Broder4, H. Michael Belmont5, Peter M. Izmirly5, Beatrice Goilav6, Thomas Tuschl3, Chaim Putterman6 and Jill P. Buyon7, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Rockefeller University, New York, NY, 4Medicine/Rheumatology, Division of Rheumatology, Albert Einstein College of Med, Bronx, NY, 5New York University School of Medicine, New York, NY, 6Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 7Medicine, New York University School of Medicine, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, lupus nephritis and skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The premise of this study is that the impact of renal injury in lupus nephritis is widespread with consequences to resident cells in other tissue beds, such as non-sun exposed non-lesional skin. Reflection of a relevant pathway in renal tissue by a more readily accessible compartment would be an advance. Single-cell transcriptional states may provide a framework for understanding how in vivo biological function emerges from complex cell ensembles.

Methods: As an approved nested study within the SLE Accelerated Medicines Partnership (AMP), single cell RNAseq was performed on cell suspensions prepared from ~2 mm punch biopsies of non-lesional non-sun exposed skin from the buttocks of 3 SLE patients with proteinuria and known ISN/RPS Class and 3 healthy controls. Libraries were prepared on the Fluidigm C1 platform followed by sequencing on an Illumina HiSeq 2500. Differential expression was used to assign in vivo cell-type compositions through unsupervised sampling and modeling of transcriptional states in single cells. We generated 36 single-cell data sets with on average 852 genes/cell and 37% of reads mapping to the reference genome. Data are expressed as log2 transcripts per million.

Results: Based on expression of COL1A1, COL1A2, COL3A1, MFAP5 and MFAP4, assignments yielded 12 fibroblasts from 3 patients. From the one Class II subject there were 5 single cell transcriptomes. The other 2 subjects (1 Class IV,V; 1 Class III,V) yielded 7 single cell transcriptomes. From the 3 controls, there were 22 transcriptomes. In the aggregate data for controls, the top one thousand genes were used for a cluster analysis of categories in the DAVID annotation. In the controls, a prominent cluster with an enrichment score of 5.60, in the extracellular matrix category, was significantly represented in the set (P=3.77E-12). The DAVID annotation of skin transcriptomes from subjects with proliferative nephritis resembled the healthy controls; however, closer scrutiny showed differences as highlighted in Table 1 which focuses on the expression of an annotated gene set of  transcripts in the extracellular matrix category (11 are shown) comparing case vs control. In dermal fibroblasts from subjects with proliferative disease the expression of anti-fibrotic genes was increased while pro-fibrotic genes were attenuated. This result suggests that an event involving localized fibrosis of renal tissue yields at distant sites (such as the skin), a fibroblast transcriptome which exerts a countermeasure to forestall fibrosis. The profile of transcripts of subjects with class II resembled controls.

Conclusion: Single-cell RNAseq is feasible and informative in cell specific transcriptome analysis of fresh non-lesional skin biopsies from SLE patients with a spectrum of active renal disease. The expression of fibroblasts and genes reflective of anti-fibrotic pathways support application of this novel approach to study readily accessible tissue.  

Table 1
  Case Control
Anti-fibrotic
TIMP1 8.78** 6.04
TIMP3 9.03 7.82
CTHRC1 8.24 6.56
Pro-fibrotic
COL1A2* 9.65 13.25
MFAP4 7.08 8.51
FBLN1* 6.61 10.31
FN1 8.83 9.32
ELN 7.15 8.52
SPARC* 5.22 10.88
CCDC80* 5.13 10.98
TGFBR2 8.13 9.69
*P<0.05, case vs control, **Units, log((average of transcripts),2)

 


Disclosure: R. M. Clancy, None; E. Der, None; K. Akat, None; A. R. Broder, None; H. M. Belmont, None; P. M. Izmirly, None; B. Goilav, None; T. Tuschl, None; C. Putterman, exagen, 2; J. P. Buyon, Exagen, 2,GSK, 5,UCB, 5,Abbvie, 5,Immunarray, 5.

To cite this abstract in AMA style:

Clancy RM, Der E, Akat K, Broder AR, Belmont HM, Izmirly PM, Goilav B, Tuschl T, Putterman C, Buyon JP. Dermal Fibroblasts from Patients with Lupus Nephritis Express an Anti-Fibrotic Transcriptome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dermal-fibroblasts-from-patients-with-lupus-nephritis-express-an-anti-fibrotic-transcriptome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dermal-fibroblasts-from-patients-with-lupus-nephritis-express-an-anti-fibrotic-transcriptome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology